ISRCTN50040185 https://doi.org/10.1186/ISRCTN50040185

NuProtect: Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe haemophilia A

Submission date
11/09/2013

Recruitment status
No longer recruiting

Registration date
22/10/2013

Overall study status
Completed

Last Edited
23/05/2022

Condition category
Haematological Disorders

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

Plain English summary of protocol

Background and study aims
FVIII concentrates are the only available treatment for patients with severe haemophilia A. However, patients are at risk of developing resistance (inhibitor) to FVIII, which stops the treatment from working, and patients may also suffer from an allergic reaction. The drug under investigation, human-cl rhFVIII, is a newly developed recombinant FVIII concentrate from a human cell line, which may have less immunogenic potential (ability to provoke an immune response) compared to FVIII concentrates from hamster cell lines or plasma-derived FVIII concentrates. The main aim of the study is to investigate the immunogenicity of the new product in previously untreated patients with severe haemophilia A. This population is at the highest risk of developing inhibitors. Previous studies of the new product in already treated patients (adults and children) did not show a single case of inhibitor development.

Who can participate?
Previously untreated patients with severe haemophilia A.

What does the study involve?
All patients will receive the newly developed recombinant FVIII concentrate injection. The study involves regular blood sampling to screen for inhibitors. All patients adverse events are documented.

What are the possible benefits and risks of participating?
Human-cl rhFVIII may have less immunogenic potential compared to recombinant FVIII concentrates from hamster cell lines or plasma-derived FVIII concentrates. However, as for all FVIII concentrates, patients are at risk of developing an inhibitor to FVIII and may suffer from an allergic reaction.

Where is the study run from?
The study is planned to be conducted at about 45 study sites in 16 countries worldwide.

When is the study starting and how long is it expected to run for?
The study started in March 2013, and is planned to be completed in 2018.

Who is funding the study?
Octapharma AG, Switzerland

Who is the main contact?
Martina Jansen
Octapharma PPG
Clinical Research & Development Haematology
Oberlaaerstrasse 235
1100 Vienna, Austria

Contact information

Type(s)
Scientific

Contact name
Dr Raina Liesner

Contact details
Great Ormond Street Hospital for Children, NHS Trust
Haemophilia Centre
Great Ormond Street
London
United Kingdom
WC1N 3JH

Additional identifiers

EudraCT/CTIS number
2012-002554-23

IRAS number

ClinicalTrials.gov number
NCT01712438

Secondary identifying numbers
GENA-05

Study information

Scientific Title
Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe haemophilia A: a prospective, multinational, open-label, non-controlled study

Study objectives

Immunogenicity of Human-cl rhFVIII in previously untreated patients with severe haemophilia A is low.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Canada, HIREB Hamilton: 11 March 2013
Germany, Ethics Committee University Münster: 08 July 2013
Spain, Vall d`Hebron, Barcelona: 11 January 2013
France, CPP Ouest V, Nanterre: 07 February 2013
UK, NRES Committee London-Central: 19 February 2013
Georgia, Committee of Institute of Haematology, Tiflis: 17 January 2013
Moldova, National Ethics Committee, Chisinau: 29 January 2013
Poland, EC Medical University Warsaw: 12 February 2013
Russia, Izmailowska EC: 26 June 2013
Ukraine, National Academy of Medical Science: 04 February 2013

Study design
Prospective multicentre multinational open-label non-controlled study

Primary study design
Interventional

Secondary study design
Non randomised study

Study setting(s)
Hospital

Study type(s)
Screening

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Severe haemophilia A

Interventions
There is only one study arm. All patients receive the same investigational medicinal product (IMP) intravenously. The dose, frequency and duration are flexible, and depend on the individual clinical condition of the patient.

Intervention Type
Drug

Phase
Phase III

Drug/device/biological/vaccine name(s)
Human-cl rhFVIII

Primary outcome measure
The immunogenic potential of the IMP. Each patient is tested for the development of inhibitors at treatment start, every three to four exposure days to the IMP, latterly every ten exposure days (latest every three months).

Secondary outcome measures
Safety, efficacy and tolerability: Efficacy (by assessing each treatment of a bleeding episode, or the rate of bleeds in case of prophylactic treatment) and safety (adverse events) are observed during the entire study duration, which is planned for a total of 100 exposure days with the IMP, but not longer than 5 years.

Overall study start date
01/03/2013

Completion date
24/03/2020

Eligibility

Key inclusion criteria
1. Male, no age limitations, but due to the required patient population it can be expected that the majority of patients going to be included are babies and small children.
2. Severe haemophilia A (FVIII:C < 1%)
3. No previous treatment with FVIII concentrates or other blood products containing FVIII
4. Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted (obtained from the patients parent/legal guardian)

Participant type(s)
Patient

Age group
Child

Sex
Male

Target number of participants
100

Key exclusion criteria
1. Diagnosis with a coagulation disorder other than haemophilia A
2. Severe liver or kidney disease (alanine amino transferase (ALT) or aspartate transaminase (AST) levels >5 times of upper limit of normal, creatinine >120 µmol/L)
3. Concomitant treatment with any systemic immunosuppressive drug
4. Participation in another interventional clinical study currently or during the past 4 weeks.

Date of first enrolment

01/03/2013

Date of final enrolment
30/06/2016

Locations

Countries of recruitment
Brazil

Canada

Colombia

England

France

Georgia

Germany

India

Moldova

Morocco

Poland

Russian Federation

Spain

Ukraine

United Kingdom

United States of America

Venezuela

Study participating centre
Great Ormond Street Hospital for Children, NHS Trust
London
United Kingdom
WC1N 3JH

Sponsor information

Organisation
Octapharma AG (Switzerland)

Sponsor details
Seidenstrasse 2
Lachen
Switzerland
8853

Sponsor type
Industry

Website
http://www.octapharma.com

ROR
https://ror.org/002k5fe57

Funder(s)

Funder type
Industry

Funder Name
Octapharma AG (Switzerland)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?

Interim results article	interim results	01/03/2018	14/05/2019	Yes	No
Basic results	EU Clinical Trials Register results	23/08/2020	20/05/2022	No	No
Basic results	ClinicalTrials.gov results	21/10/2019	23/05/2022	No	No